Bli medlem
Bli medlem

Du är här


Camurus AB: Nomination Committee appointed in respect of AGM 2016 in Camurus

Lund - 4 February 2016 - According to the instruction for Nomination
Committee in Camurus AB adopted at the extraordinary general meeting
held on 15 October 2015, the Nomination Committee for the annual
general meeting 2016 shall be composed of representatives of the
three largest shareholders in terms of voting rights as of 31
December 2015, along with the Chairman of the Board of Directors. The
composition of the Nomination Committee has now been established, and
Camurus today announced that the Nomination Committee in respect of
the AGM 2016 consists of the following persons who together represent
approximately 67 percent of the number of shares and votes in the
company based on the last known shareholder information.

· Per Sandberg, representing Sandberg Development AB
· Jan Andersson, representing Swedbank Robur Fonder
· Mikael Hanell, representing Catella Fonder
· Per Olof Wallström, Chairman of the Board

Shareholders who wish to submit proposals to the Nomination Committee
are welcome to contact the Nomination Committee at the company's
address. Proposals shall be submitted in due time before the Annual
General Meeting, but not later than 15 March 2016, to ensure that the
proposals can be considered by the Nomination Committee.

About Camurus
Camurus is a Swedish research-based pharmaceutical company committed
to developing and commercialising innovative and differentiated
medicines for the treatment of severe and chronic conditions. New
drug products with best-in-class potential are conceived based on the
proprietary FluidCrystal® drug delivery technologies and an extensive
R&D expertise. Camurus' clinical pipeline includes products for
treatment of cancer, endocrine diseases, pain and addiction,
developed in-house and in collaboration with international
pharmaceutical companies. The company's shares are listed on Nasdaq
Stockholm under the ticker "CAMX". For more information, visit

For more information
Per Olof Wallström, Chairman of the Board
Tel. +46 709 42 95 20

The information in this press release is disclosed by Camurus AB in
accordance with the Swedish Securities Markets Act and/or the Swedish
Financial Instruments Trading Act. The information was submitted for
publication at 08.00 a.m. on 4 February 2016.


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.